An incremental enhancement of BRCA1 and CD8 + T-cell-dependent anti-tumour effects has been observed with the addition of anti-programmed death (PD)-1 or PD-ligand1 (PD-L1) agents to PARP inhibition [18]. The gene discussed is CD274; the disease is neoplasm.